Eikon Therapeutics

Eikon Therapeutics, based in Millbrae, California, the United States, is a biotechnology company. A drug discovery company that also has offices in New York and Jersey City and lists clinical-stage oncology, immunology and neuroscience programmes on its pipeline page, including TLR7/8, PARP1, PARP1-CNS penetrant, AR, VCP and AR-v7 targeted programmes. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing EIK1001, EIK1004-001 (IMP1707-001), IMP1734 and EIK1005 in melanoma, non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, colorectal cancer and endometrial cancer. The largest, NCT07365319 (A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer), plans to enrol 750 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.